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Abstract
Background: Chordoma was a typically slow-growing tumor. The therapeutic approach to chordoma had
traditionally relied mainly on surgical therapy. And the main reason for therapeutic failure was resistance to
chemotherapy and radiotherapy. However the refractory mechanism was not clear. The aim of this study was to
investigate the expression of three genes (MDR1, HIF-1a and MRP1) associated with resistance to chemotherapy
and radiotherapy in chordoma and chordoma cell line CM-319.
Materials and methods: Using immunohistochemical techniques, the expression of MDR1, HIF-1a and MRP1 was
investigated in 50 chordoma specimen. Using RT-PCR and Western blot, the expression of MDR1, HIF-1a and MRP1
was investigated in chordoma and chordoma cell line CM-319.
Results: Expression of MDR1, HIF-1a and MRP1 was observed in 10%, 80% and 74% of all cases, respectively.
Expression of MRP1 was correlated with HIF-1a. On the other hand, expression of MDR1 was not correlated with
the expression of HIF-1a or MRP1. The expression of HIF-1a and MRP1 was observed, but MDR1 was not observed
in chordoma and CM-319.
Conclusion: Expression of HIF-1a and MRP1 was observed in most chordoma specimen and CM-319 cell line;
expression of HIF-1a correlated with MRP1. HIF-1a and MRP1 may play a role in the multidrug resistance of
chordoma to chemotherapy.
Introduction
Chordoma, a primary malignant tumor of the skeleton,
was considered to develop from a remnant of notochordal
cells in the midline skeletal axis [1]. The most common
sites are the skull base and the sacrococcygeal region. It is
typically slow-growing tumor, and initial symptoms are
usually related to local progression of the disease with sub-
sequent compression of adjacent structures. The natural
course of chordoma is quite grim; most patients do not
survive 10 years because of high local recurrence rates
[2,3]. The therapeutic approach to chordoma has tradi-
tionally relied heavily on surgical control. More recently,
radiation therapy has been demonstrated to be a valuable
modality for local control, particularly with the advent of
charged particle radiotherapy. Medical therapy continues
to be suboptimal in chordoma which is relatively
refractory to cytotoxic chemotherapy. The main reason for
therapeutic failure in cases of chordoma involves resis-
tance to chemotherapy and radiotherapy. The refractory
reason to chemotherapy and radiotherapy may be asso-
ciated to the over-expression of some multidrug resistance
related genes and hypoxia inducible factor-1a. These fac-
tors could also provide potential targets for studies on
novel therapeutic procedures.
Multidrug resistance is a frequent cause of treatment
f a i l u r ei nc a n c e rp a t i e n t s .O n em e c h a n i s mo fM D Ri s
over-expression of ATP-binding cassette (ABC) trans-
porter proteins that function as a drug efflux pump.
These ABC transporter proteins include P-glycoprotein
(P-gp) [4], which is a member of the multidrug resis-
tance-associated protein (MRP) family, the recently
identified breast cancer resistance protein (BCRP), and
the lung resistance-related vault protein (LRP) identified
as the major vault protein (MVP) which are also asso-
ciated with MDR.
The hypoxia-inducible factor (HIF)i sa na l p h a( a)/
beta (b) heterodimeric DNA binding complex and
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induction of genes relevant to tumor progression, such
as angiogenesis, metabolism, cellular growth, metastasis,
and apoptosis. HIF-1a has emerged as an attractive tar-
get for cancer therapy [5,6].
Over-expression of P-gp and MRP is generally
believed to be the mechanism responsible for MDR of
tumor cells. Hypoxia is a common feature of many
malignant tumors. HIF-1 is a key factor in altering the
biological characteristics of tumors [7-9]. Many studies
indicate that hypoxia helps to improve chemotherapy
and radiotherapy resistance of tumors [10-12].
To our knowledge, the mechanism of multidrug resis-
tance to chemotherapy remained largely unknown in
chordoma. The present study aimed to investigate the
relationship between the expression of HIF-1a, MDR1
and MRP1 in spinal chordoma as well as their prognos-
tic and predictive value.
Materials and methods
Tumors
A total of 50 primary conventional chordoma specimens
between the year 2000 and 2008 (32 males and 18
females) were used for the study. The lesions were
obtained from the Department of Pathology (Orthopedics
O n c o l o g yI n s t i t u t e ,T a n g d uH o s p i t a l ,P .R .C h i n a ) .
7 lesions were located in the cervical to lumbar spine and
43 in the sacrococcygeal region, at the age ranging from
31 to 80 years old (the mean age was 58). The diagnosis
of all cases was confirmed by the co-expression of S-100
protein, Cytokeratin, EMA and Vimentin. Histological
sections obtained at biopsy or surgically resected speci-
mens were routinely stained with haematoxylin and eosin
for diagnostic purpose. All the specimens were reviewed
and diagnosed by two pathological experts. No patient in
this study had undergone chemotherapy or radiotherapy
before surgery. Nucleus pulposus tissues were resected in
15 patients diagnosed as lubar intervertebral disc protru-
sion as control. The following clinicopathological and
immunohistochemical studies were conducted using sec-
tions from 10% formalin fixed paraffin-embedded tissues,
highlighting the representative areas of the tumor. Light
microscopic parameters and immunohistochemical ana-
lysis using the antibodies were performed in all 50 cases.
For RT-PCR, Western blot, 10 chordoma tissue sam-
ples and nucleus pulposus tissues were snap-frozen and
stored at -80°C until use. Surgical samples were kept in
RPMI 1640 cell culture medium before isolation of
chordoma cells (within 2 h after removal).
Cell culture
Human chordoma cell line CM-319 was derived from a
case of sacral chordoma [13]. The cell line was main-
tained at 37°C under 5% CO2 in RPMI 1640 medium
(Invitrogene, USA) supplemented with 10% FCS (Gibco,
USA), penicillin (100 units/ml), streptomycin (100 μg/
ml) and 1% (v/v) L-glutamine.
Immunohistochemical study
T h ec h o r d o m at i s s u es a m p l e sa n dC M - 3 1 9c e l l sw e r e
investigated immunohistochemically for the expression
of MDR1 (monoclonal, dilution 1:500; Santa Cruz Bio-
technology, USA), MRP1 (monoclonal, dilution 1:500;
Santa Cruz Biotechnology, USA), HIF-1a (monoclonal,
dilution 1:500; Santa Cruz Biotechnology, USA). The
sections (4 μm) were deparaffinized in xylene and then
rehydrated through graded alcohols to water. Antigen
retrieval for all the studied sections was performed in a
one-step procedure with the EDTA (PH 8.0) in a micro-
wave oven by heating for 5 minutes. Endogenous perox-
idase activity was blocked using 30% H2O2 for 30 min.
Nonspecific binding was blocked with 5% goat serum in
phosphate buffer solution (PBS). Sections were incu-
bated with the primary antibodies at the reference work-
ing concentration overnight at 4°C. After washed three
times with PBS, secondary antibodies, biotinylated anti-
mouse or rabbit immunoglobulins (dilution 1: 50, Dako,
Copenhagen, Denmark) were applied for 30 minutes at
room temperature. Detection was performed using the
ChemMate™ Envision +HRP/DAB kit (Dako, Copenha-
gen, Denmark). 3’-3’-Diaminobenzidine substrate was
used as a chromogen, according to the manufacturer’s
instructions. Sections were counterstained with hema-
toxylin. Staining was evaluated independently by two
pathologists.
The degree of staining was graded semi-quantitatively
according to the percentage of stained cells and their
staining intensity. In spinal chordoma, expression of
HIF-1a,M D R 1a n dM R P 1w a ss c o r e da sf o l l o w s :0 ,
none; 1, <10%; 2, 10-50%; and 3, >50% [14-18].
RNA isolation and reverse transcription-polymerase
chain reaction (RT-PCR)
Total RNA was isolated either from frozen tissue or
CM-319 cells with Trizol reagent (Invitrogen, USA).
cDNA was prepared according to standard methods:
RNA was reverse-transcribed with oligo(dT) primer
using 1 μg total RNA in a total volume of 20 μl contain-
ing transcription buffer, RNase Inhibitor, Prime Script™
RTase. For PCR, 30 cycles of denaturation (94°C for
45s), annealing (60°C for 45s), and elongation (72°C for
1 min) was performed using the following primer pairs
for HIF-1a [ 1 9 ] :f o r w a r d :5 ’-TGGACTCTGATCATCT-
GACC-3’, reverse: 5’-CTCAAGTTGCTGGTCATCAG-
3’, which yielded a 434-bp product. 30 cycles of dena-
turation (95°C for 1 min), annealing (55°C for 60s), and
elongation (72°C for 1 min) were performed using the
following primer pairs for MDR1 [20]: forward:
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TCCAATTTTGTCACCAATTCC-3’, which yielded a
259-bp product.35 cycles of denaturation (95°C for 30s),
annealing (50°C for 1 min), and elongation (72°C for
1 min) were performed using the following primer pairs
for MRP1 [ 2 1 ] :f o r w a r d :5 ’-TCAGCCCTTCCTGACAA
GCT-3’, reverse: 5’-TCTCTGCTGCAGGAGGTCCG-3’,
which yielded a 318-bp product. The GAPDH [22] con-
trol PCR was performed using the following primer
pairs: forward: 5’-ACCACCATGGAGAAGGCTGG-3’,
reverse: 5’-CTCAGTGTAGCCCAGGATGC-3’,w h i c h
yielded a 527-bp product. For negative controls, the
PCR reaction was performed without prior reverse tran-
scription. Amplified cDNA was visualized by ethidium
bromide staining on 1.5% agarose gels on a Bio-Rad gel
scanner (Bio-Rad, USA).
Western Blot
The chordoma cell line CM-319 and frozen nucleus pul-
posus tissues were harvested and lysed with a cold RIPA
protein lysis buffer for 30 minutes on ice. The lysates were
transferred to Eppendorf tubes and clarified by centrifuga-
tion at 12,000 g for 10 minutes at 4°C. The supernatant
was kept in -80°C for future use. The BCA method was
performed to determine the protein concentration in the
supernatant. Samples (30 μg of total protein each) were
boiled at 95°C for five minutes and loaded onto SDS-
PAGE (5% stacking gel and 8% separating gel), followed
with a separation at 80 volts for about two hours and sub-
sequent transferred onto a nitrocellulose membrane. The
membrane was blocked in 5% defatted milk for 1 hour at
room temperature, and was then incubated in the primary
antibodies diluted in 5% defatted milk/TBST overnight at
4°C (MDR1 1:200, mouse anti-human, Santa Cruz; MRP1,
1:200, rabbit anti-human, Santa Cruz; HIF-1a, 1:200, rab-
bit anti-human, Santa Cruz). The membrane was washed
three times with TBST and incubated with the second
antibodies for an hour at room temperature, then washed
three times with TBST again. The enhanced chemilumi-
nescene (ECL) system (Piece) was used for detection of
MDR1, HIF-1a and MRP1. Protein bands were visualized
and quantified using Quantity-One software (Bio-Rad
USA). The MDR1, HIF-1a and MRP1 bands were visua-
lized at an apparent molecular weight of 170, 120 and
190 kDa, respectively.
Statistical analysis
Relationship between the expression of HIF-1a,M D R 1
and MRP1 were defined using Kruskal-Wallis test (x
2 or
Fisher’s exact test). Correlations among three markers
were described using the Spearman rank correlation
test. Correlations between the expression of three mar-
kers and patient age, MIB-1 labelling index were esti-
mated using the Mann-Whitney U test. All calculations
and analyses were performed with SPSS 12.0 for Win-
dows. Significance was considered to be P < 0.05.
Results
Expression of HIF-1a, MRP1 and MDR1 in human
chordomas
Different pattern of immunoreactivity was found as mem-
branous or cytoplasmic staining for MDR1 and MRP1,
while cytoplasmic, part of nuclear positive for HIF-1a.
MDR1 positive staining was found in five (10%) of the 50
lesions which scored 1 (Figure 1E, F), and scored 0 in the
remaining lesions. Thirteen of the 50 lesions were assigned
to MRP1 score 0; three of the lesions scored 1; eighteen
lesions scored 2; and sixteen lesions scored 3. Ten of the
50 lesions were assigned to HIF-1a score 0; four of the
lesions scored 1; fourteen lesions scored 2; and twenty-two
lesions scored 3. As a consequence, 37 (74%) lesions
expressed MRP1 with score ≥1; 16 (32%) lesions showed
strong expression with score3( F i g u r e1 C ,D ) .4 0( 8 0 % )
lesions expressed HIF-1a with score ≥1; 22 (44%) lesions
showed strong expression with score 3 (Figure 1A, B).
Expression of HIF-1a in chordoma was much higher than
that in nucleus pulposus; expressiong of MRP1 in chor-
doma was also much higher than that in nucleus pulposus;
but expression of MDR1 in chordoma was not different
from that in nucleus pulposus. (Table 1)
Correlation of antibody expression in chordomas tumors
Using Kruskal-Wallis test, we examined the relationship
among MDR1, MRP1 and HIF-1a. For spinal chordoma
tumors, whether primary or recurrent, we found that
the overall immunoreactivity score of MRP1 or HIF-1a
was higher in cases showing expression of MDR1. There
was no correlation between the expression of MDR1,
MRP1, HIF-1a expression and patient age, gender.
There was no relationship between MDR1 expression
a n de i t h e rM R P 1o rH I F - 1 a expression. There was a
significant correlation between HIF-1a expression and
MRP1 expression level. Chordomas that had high MRP1
expression were also likely to have high HIF-1a expres-
sion. (Table 2)
RT-PCR analysis of HIF-1a, MDR1 and MRP1 in
chordoma cells
Anaylsis of HIF-1a, MDR1 and MRP1 mRNA was con-
ducted in CM-319 and chordoma by RT-PCR analysis
using three pairs of primers designed for the human
HIF-1a, MDR1 and MRP1 sequences. A 437-, 257-,
328-bp fragment should be obtained for HIF-1a, MDR1
and MRP1 as expected, respectively. Amplification of
547-bp fragment of GAPDH w a su s e da sa ni n t e r n a l
control for the integrity of the isolated mRNA. A posi-
tive HIF-1aand MRP1, but a negative MDR1 was
observed in CM-319 cells (Figure 2).
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Page 3 of 7Western blot of HIF-1a, MDR1 and MRP1 in chordoma cells
Expression of HIF-1a, MDR1 and MRP1 in CM-319
cells was detected by immunoblotting. The results
showed no positive band with a molecular weight of
170 KD in CM-319, which indicated the negative
Figure 1 Immunohistochemical staining of HIF-1a, MDR1 and MRP1 in chordoma, CM-319 and nucleus pulpous.W i t h
immunohistochemical staining, the expression of chemotherapy resistant proteins using primary antibody to HIF-1a (A, B, G), MDR1 (E, F, I) and
MRP1 (C, D, H) was determined in chordoma (B, D, F) and CM-319 (A, C, E). Intense membrane and cytoplasmic staining of MRP1 (×400) and
cytoplasmic and nuclus staining of HIF (×400). Negative immunostaining of MDR1 was found in chordoma and CM-319. In control, negative
immunostaining of HIF-1, MRP1 and MDR1 (G, H, I) was found in nucleus pulposus.
Table 1 Expression of HIF-1a, MRP1 and MDR1 in
chordoma tissue and nucleus pulposus tissue
positive negative positive rate c
2 P
HIF-1a(n)
chordoma 40 10 80% 18.55 <0.005
nucleus pulposus 3 12 20%
MRP1 (n)
chordoma 37 13 74% 11.10 <0.005
nucleus pulposus 4 11 26.7%
MDR1 (n)
chordoma 5 45 10% 0.343 >0.5
nucleus pulposus 3 12 20%
Table 2 Correlation with the expression of HIF-1a, MRP1
HIF-1a(n) MRP1(n) rP
negative 0 10 13 0.8 <0.01
14 3
positive 2 14 18
32 2 1 6
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Page 4 of 7expression of MDR1 in CM-319, but strong positive
expression of HIF-1a and MRP1 at 120 KD and 190 KD
in the membrane in CM-319 cells. These results were
reproduced in repeat experiments of independent mem-
brane preparations and a representative blot is shown in
Figure 3.
Discussion
Chordoma was not reported to be sensitive to che-
motherapy, similar to many other low-grade malignan-
cies. Accordingly, chemotherapy response had been
reported in patients with high-grade dedifferentiated
chordoma, which represented <5% of all chordoma [23].
The modern multi-modality therapeutic approach to
chordoma, combining surgery with radiotherapy and
chemotherapy, resulted in high cure rates even in
advanced stage disease, with the pivotal role attributed
to chemotherapy. However, there were still cases which
exhibited either primary or secondary drug resistance
with dismal outcomes [24]. Drug resistance was a major
obstacle for clinical management and was attributable to
several processes taking place in many kinds of tumor
cells. One of these processes was the decreased accumu-
lation of drugs within cancer cells due to drug efflux
mediated by ABC multidrug transporters. Over-expression
of these transporters was an adverse prognostic factor in a
number of cancers. The significance of the expression of
these ABC proteins in chordoma had not yet been
reported.
Cellular adaptation to hypoxia was a critical step in
tumor progression [25]. Hypoxia occurred during several
pathophysiological processes including tumorigenesis,
which was a reduction in the normal level of tissue oxy-
gen tension. Hypoxic cancer cells might undergo a series
of genetic and metabolic cha n g e st h a ta l l o w e dt h e mn o t
only to survive and proliferate but also to become more
resistance to conventional therapies including ionizing
radiation and chemical agents. These hypoxic adaptations
made the tumors more difficult to treat and confer
increased resistance to death from chemotherapy and
radiotherapy. In response to hypoxia, cells altered the
expression of genes that encoded protein products
involved in increasing oxygen delivery and activated
alternate metabolic pathways that did not require oxygen.
This hypoxic response was chiefly regulated by HIF-1a.
Magnon’s [10] findings supported a crucial role for
angiogenesis inhibitors in shifting the fate of radiation-
induced HIF-1a activity from hypoxia-induced tumor
radioresistance to hypoxia-induced tumor apoptosis. Sul-
livan [12] determined the effects of hypoxia on multiple
forms of drug-induced death in human MDA-MB-231
breast carcinoma cells. These results supported a require-
ment for HIF-1 in the adaptations leading to drug resis-
tance and revealed that decreased drug-induced
senescence was also an important contributor to the
development of hypoxia-induced resistance. Nardinocchi
[26] reported that the mechanistic explanation of
Figure 2 RT-PCR analysis of MDR1, HIF-1a and MRP1
messenger RNA (mRNA) expression in CM-319 cell line and
chordoma. A significant HIF-1a and MRP1 mRNA expression was
observed, but a negative MDR1 expression was observed in CM-319
cell line and chordomas. But negative expression of MDR1, HIF-1a
and MRP1 messenger RNA (mRNA) in nucleus pulposus. Amplification
of a 547-bp fragment of GAPDH was used as an internal control for
the integrity of the isolated mRNA. Lane 1: Marker; Lane 2: GAPDH;
Lane 3: HIF-1a; Lane 4: MRP1; Lane 5: MDR1.
Figure 3 Western blot analysis of HIF-1a,M D R 1a n dM R P 1
protein in tumor tissues and CM-319 cell line. Lane1: MRP1;
lane2: HIF-1a; lane 3: MDR1; lane4: conditioned medium. Molecular
weight markers are identificated in the left side (kD).
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Page 5 of 7hypoxia-induced chemoresistance involved upregulation
of HIF-1 pathway and inhibition of the p53 pathway that
were partly interconnected by the hypoxia-induced HIPK2
deregulation. They showed for the first time that hypoxia-
induced HIPK2 deregulation was counteracted by zinc
that restored HIPK2 suppression of HIF-1 pathway and
reactivated p53 apoptotic response to drug, underscoring
the potential use of zinc supplementation in combination
with chemotherapy to address hypoxia and improve
tumor treatment. It has been recently reported [27,28]
that the transcription of MDR1 gene was controlled by
hypoxia; HIF-1 binding to a putative binding site of
human MDR1 promoter was critical for the transcription.
Song [29] demonstrated that hypoxia-induced chemoresis-
tance to cisplatin and doxorubicin in NSCLC cells was
through the HIF pathway. MDR1 regulation may not be
involved in hypoxia-induced chemoresistance. Combining
delivery of HIF-1a RNAi lentiviral vector with cisplatin-
related chemotherapy regimens could enable us to develop
more effective strategy for NSCLC therapy. Ding [15] sug-
gested that hypoxia induce the expression of HIF-1a and
P-gp in colon carcinoma and HIF-1a expression may be
associated with P-gp and interactively involved in the
occurrence of tumor multidrug resistance.
In this study, we described the expression of these
three different proteins associated with multidrug resis-
tance and radiotherapy in chordoma. All the tested mar-
kers exhibited some changes in their expression pattern
in chordoma compared with normal nucleus pulpous.
The most prominent reduction in expression was
observed for MDR1 which was very weakly expressed or
unexpressed in more than 50% of the chordoma samples
studied. To our knowledge, this was the first study on
genes associated with resistance to chemotherapy and
radiotherapy in spinal chordoma. The current results
showed that MRP1was expressed in the membranous
and intracellular regions; HIF-1a was expressed in the
cell cytoplasmic and nuclear regions, whereas MDR1 was
not expressed in the chordoma tissues or CM-319 cell.
ABC multidrug transporters also played an important
role in the establishment of important biological barriers
such as the placenta, the blood-brain barrier, and the
blood-testes barrier. Although the over-expression of
these transporters was a common phenomenon in che-
moresistant tumor cells, we found that MRP1 and
HIF-1a expression was upregulated in most chordoma
tissues in comparison to normal tissues. It had been
proposed that upregulation of ABC multidrug transpor-
ters in cancers may play a role in tumorigenesis by
enhancing exposure of tissues to carcinogenic xenobio-
tics. Interestingly, the expression of MDR1 was not
inversely expressed in the chordoma tissues.
New data on HIF-1 signaling and the potential for tar-
geted therapies, including combinations of hormonal
therapies for cancer and selective investigational HIF-1a
inhibiting small molecules would be discussed. Another
mechanism by which hypoxia could increase chemore-
sistance was to enhance the expression of MDR1 gene
via a HIF-1-dependent regulation [30,31].
Abbreviations
HIF-1a: hypoxia-inducible factor alpha (a) heterodimeric; MDR1/P-GP:
multidrug resistance gene/P-glycoprotein; MRP1: multidrug resistance-
associated protein 1
Acknowledgements
This work was supported by grants from the National Natural Science
Foundation of P. R. China (No. 30873027, No.30973409 and No.30330610)
and major issues Foundation of health department in Shaaxi province (No.
2010K13-02-05). The authors thank Dr Lianjia Yang and Ms Yanhua Wen
(Orthopadepics Department, Tangdu Hospital, the Fourth Military Medical
University, Xi’an, P. R. China) for their pathological diagnosis. We thank Ms
Yunyan Liu and Ms Qiong Ma (Orthopadepics Department, Tangdu Hospital,
the Fourth Military Medical University, Xi’an, P. R. China) for their skillful
technical assistance. We are also grateful to Dr Tongtao Yang, Dr Dianzhong
Zhang, Dr Yong Zhou and Dr Minghua Zhang (Orthopadepics Department,
Tangdu Hospital, the Fourth Military Medical University, Xi’an, P. R. China) for
their helpful discussion.
Authors’ contributions
ZJ and HL conceived of the study, and participated in its design and
coordination and helped to draft the manuscript. YH, XQ and XC carried out
the molecular genetic studies. ZL and DF participated in its design and
coordination. BM and QF participated in the conception and the design of
the analysis. All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 6 October 2010 Accepted: 8 December 2010
Published: 8 December 2010
References
1. Chugh R, Tawbi H, Lucas DR, Biermann JS, Schuetze SM, Baker LH: Chordoma:
the nonsarcoma primary bone tumor. Oncologist 2007, 12:1344-1350.
2. Azzarelli A, Quagliuolo V, Cerasoli S, Zucali R, Bignami P, Mazzaferro V,
Dossena G, Gennari L: Chordoma: natural history and treatment results in
33 cases. J Surg Oncol 1988, 37:185-191.
3. Baratti D, Gronchi A, Pennacchioli E, Lozza L, Colecchia M, Fiore M,
Santinami M: Chordoma: natural history and results in 28 patients
treated at a single institution. Ann Surg Oncol 2003, 10:291-296.
4. Cordon-Cardo C, O’brien JP, Casals D, Rittman-Grauer L, Biedler JL,
Melamed MR, Bertino JR: Multidrug-resistance gene (P-glycoprotein) is
expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad
Sci USA 1989, 86:695-698.
5. Kunz M, Ibrahim SM: Molecular responses to hypoxia in tumor cells. Mol
Cancer 2003, 2:23.
6. Harris AL: Hypoxia–a key regulatory factor in tumour growth. Nat Rev
Cancer 2002, 2:38-47.
7. Mabjeesh NJ, Amir S: Hypoxia-inducible factor (HIF) in human
tumorigenesis. Histol Histopathol 2007, 22:559-572.
8. Jensen RL, Ragel BT, Whang K, Gillespie D: Inhibition of hypoxia inducible
factor-1alpha (HIF-1alpha) decreases vascular endothelial growth factor
(VEGF) secretion and tumor growth in malignant gliomas. J Neurooncol
2006, 78:233-247.
9. Nagle DG, Zhou YD: Natural product-based inhibitors of hypoxia-
inducible factor-1 (HIF-1). Curr Drug Targets 2006, 7:355-369.
10. Magnon C, Opolon P, Ricard M, Connault E, Ardouin P, Galaup A, Métivier D,
Bidart JM, Germain S, Perricaudet M, Schlumberger M: Radiation and
inhibition of angiogenesis by canstatin synergize to induce HIF-1alpha-
mediated tumor apoptotic switch. J Clin Inves 2007, 117:1844-1855.
Ji et al. Journal of Experimental & Clinical Cancer Research 2010, 29:158
http://www.jeccr.com/content/29/1/158
Page 6 of 711. Schnitzer SE, Schmid T, Zhou J, Brune B: Hypoxia and HIF-1alpha protect
A549 cells from drug-induced apoptosis. Cell Death Differ 2006,
13:1611-1613.
12. Sullivan R, Paré GC, Frederiksen LJ, Semenza GL, Graham CH: Hypoxia-
induced resistance to anticancer drugs is associated with decreased
senescence and requires hypoxia-inducible factor-1 activity. Mol Cancer
Ther 2008, 7:1961-1973.
13. Zhang DZ, Ma BA, Fan QY, Chang H, Wen YH: Establishment and
characteristics of a human chordoma cell line. Zhonghua Zhong Liu Za
Zhi 2003, 25:234-237.
14. Naka T, Boltze C, Samii A, Samii M, Herold C, Ostertag H, Iwamoto Y, Oda Y,
Tsuneyoshi M, Kuester D, Roessner A: Expression of c-MET, low-molecular-
weight cytokeratin, matrix metalloproteinases-1 and -2 in spinal
chordoma. Histopathology 2009, 54:607-613.
15. Zhenyu Ding, Li Yang, Xiaodong Xie, Fangwei Xie, Feng Pan, Jianjun Li,
Jianming He, Houjie Liang: Expression and significance of hypoxia-
inducible factor-1 alpha and MDR1/P-glycoprotein in human colon
carcinoma tissue and cells. J Cancer Res Clin Oncol 2010, 136:1697-1707.
16. Chen WT, Huang CJ, Wu MT, Yang SF, Su YC, Chai CY: Hypoxia-inducible
factor-1alpha is associated with risk of aggressive behavior and tumor
angiogenesis in gastrointestinal stromal tumor. Jpn J Clin Onco 2005,
35:207-213.
17. Hodorová I, Rybárová S, Solár P, Vecanová J, Mihalik J, Bohus P, Mellová Y,
Kluchová D: Multidrug resistance proteins in renal cell carcinoma. Folia
Biol (Praha) 2008, 54:187-192.
18. Mignogna C, Staibano S, Altieri V, De Rosa G, Pannone G, Santoro A,
Zamparese R, D’Armiento M, Rocchetti R, Mezza E, Nasti M, Strazzullo V,
Montanaro V, Mascolo M, Bufo P: Prognostic significance of multidrug-
resistance protein (MDR-1) in renal clear cell carcinomas: a five year
follow-up analysis. BMC Cancer 2006, 6:293.
19. Fukushima K, Murata M, Hachisuga M, Tsukimori K, Seki H, Takeda S,
Asanoma K, Wake N: Hypoxia inducible factor 1 alpha regulates matrigel-
induced endovascular differentiation under normoxia in a human
extravillous trophoblast cell line. Placenta 2008, 29:324-331.
20. Enokida H, Shiina H, Igawa M, Ogishima T, Kawakami T, Bassett WW,
Anast JW, Li LC, Urakami S, Terashima M, Verma M, Kawahara M,
Nakagawa M, Kane CJ, Carroll PR, Dahiya R: CpG hypermethylation of
MDR1 gene contributes to the pathogenesis and progression of human
prostate cancer. Cancer Res 2004, 64:5956-5962.
21. Larbcharoensub N, Leopairat J, Sirachainan E, Narkwong L,
Bhongmakapat T, Rasmeepaisarn K, Janvilisri T: Association between
multidrug resistance-associated protein 1 and poor prognosis in
patients with nasopharyngeal carcinoma treated with radiotherapy and
concurrent chemotherapy. Hum Pathol 2008, 39:837-845.
22. Neaud V, Faouzi S, Guirouilh J, Le Bail B, Balabaud C, Bioulac-Sage P,
Rosenbaum J: Human hepatic myofibroblasts increase invasiveness of
hepatocellular carcinoma cells: evidence for a role of hepatocyte growth
factor. Hepatology 1997, 26:1458-1466.
23. Fleming GF, Heimann PS, Stephens JK, Simon MA, Ferguson MK,
Benjamin RS, Samuels BL: Dedifferentiated chordoma. Response to
aggressive chemotherapy in two cases. Cancer 1993, 72:714-718.
24. Rhomberg W, Böhler FK, Novak H, Dertinger S, Breitfellner G: A small
prospective study of chordomas treated with radiotherapy and
razoxane. Strahlenther Onkol 2003, 179:249-253.
25. Dang CV, Semenza GL: Oncogenic alteration of metabolism. Trends
Biochem Sci 1999, 24:68-72.
26. Nardinocchi L, Puca R, Sacchi A, Rechavi G, Givol D, D’Orazi G: Targeting
hypoxia in cancer cells by restoring homeodomain interacting protein-
kinase 2 and p53 activity and suppressing HIF-1alpha. PLoS One 2009, 4:
e6819.
27. Comerford KM, Cummins EP, Taylor CT: c-Jun NH2-terminal kinase
activation contributes to hypoxia-inducible factor 1alpha dependent P-
glycoprotein expression in hypoxia. Cancer Res 2004, 64:9057-9061.
28. Zhu H, Chen XP, Luo SF, Guan J, Zhang WG, Zhang BX: Involvement of
hypoxia-inducible factor-1-alpha in multidrug resistance induced by
hypoxia in HepG2 cells. J Exp Clin Cancer Res 2005, 24:565-574.
29. Song X, Liu X, Chi W, Liu Y, Wei L, Wang X, Yu J: Hypoxia-induced
resistance to cisplatin and doxorubicin in non-small cell lung cancer is
inhibited by silencing of HIF-1alpha gene. Cancer Chemother Pharmacol
2006, 58:776-784.
30. Comerford KM, Wallace TJ, Karhausen J, Louis NA, Montalto MC, Colgan SP:
Hypoxia-inducible factor-1-dependent regulation of the multidrug
resistance (MDR1) gene. Cancer Res 2002, 62:3387-3394.
31. Thottassery JV, Zambetti GP, Arimori K, Schuetz EG, Schuetz JD: p53-
dependent regulation of MDR1 gene expression causes selective
resistance to chemotherapeutic agents. Proc Natl Acad Sci USA 1997,
94:11037-11042.
doi:10.1186/1756-9966-29-158
Cite this article as: Ji et al.: Expression of MDR1, HIF-1a and MRP1 in
sacral chordoma and chordoma cell line CM-319. Journal of Experimental
& Clinical Cancer Research 2010 29:158.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Ji et al. Journal of Experimental & Clinical Cancer Research 2010, 29:158
http://www.jeccr.com/content/29/1/158
Page 7 of 7